1. Home
  2. KPTI

KPTI

Karyopharm Therapeutics Inc.

Logo Karyopharm Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 2:16pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Founded: 2008 Country:
United States
United States
Employees: N/A City: NEWTON
Market Cap: 147.3M IPO Year: 2013
Target Price: $5.67 AVG Volume (30 days): 1.8M
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.25 EPS Growth: N/A
52 Week Low/High: $0.62 - $4.87 Next Earning Date: 05-02-2024
Revenue: $146,033,000 Revenue Growth: -7.03%
Revenue Growth (this year): 2.34% Revenue Growth (next year): 12.44%

Share on Social Networks:

Stock Insider Trading Activity of Karyopharm Therapeutics Inc. (KPTI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Poulton Stuart KPTI EVP, Chief Development Officer Feb 29 '24 Sell $1.17 16,311 $19,083.87 335,666 SEC Form 4
Poulton Stuart KPTI EVP, Chief Development Officer Feb 29 '24 Sell $1.20 6,155 $7,386.00 329,511 SEC Form 4
Cheng Sohanya Roshan KPTI EVP & Chief Commercial Officer Feb 29 '24 Sell $1.17 21,840 $25,552.80 398,618 SEC Form 4
Cheng Sohanya Roshan KPTI EVP & Chief Commercial Officer Feb 29 '24 Sell $1.20 5,109 $6,130.80 393,509 SEC Form 4
Paulson Richard A. KPTI President and CEO Feb 29 '24 Sell $1.17 80,470 $94,149.90 1,183,783 SEC Form 4
Paulson Richard A. KPTI President and CEO Feb 29 '24 Sell $1.20 19,374 $23,248.80 1,164,409 SEC Form 4
Mason Michael KPTI EVP, CFO & Treasurer Feb 6 '24 Sell $1.59 4,205 $6,671.23 246,945 SEC Form 4
Paulson Richard A. KPTI President and CEO Feb 6 '24 Sell $1.59 4,012 $6,365.04 821,453 SEC Form 4
Paulson Richard A. KPTI President and CEO Jan 4 '24 Sell $0.82 4,114 $3,373.48 783,465 SEC Form 4
Paulson Richard A. KPTI President and CEO Dec 4 '23 Sell $0.79 3,622 $2,861.38 787,579 SEC Form 4
Paulson Richard A. KPTI President and CEO Nov 6 '23 Sell $0.92 3,606 $3,318.60 791,201 SEC Form 4